For International Rare Disease Day, our Global Head of the Rozimab Mission, Chris Clark, shares insights about how UCB is leveraging and growing our capabilities to deliver value for specific patient populations new to UCB. Read the full article on LinkedIn.

“UCB is a company with a commitment to patient value at our core. We're structured to discover, and develop new medicines and innovative approaches to care quickly and efficiently, taking into account unique perspectives, experiences and requirements of the people living with severe and chronic conditions.

“By embracing this approach, we aim to connect targeted patient populations to cutting-edge science and, in doing so, deliver improved, differentiated experiences to people with the highest unmet needs.

“One of our newest medicines in development, rozanolixizumab, is a novel biologic therapy being investigated for the treatment of multiple IgG (immunoglobulin G) autoantibody-mediated diseases. Currently available treatments are able to partially stabilize IgG autoantibody-mediated diseases. However, they can be invasive, burdensome, costly, and can negatively impact a person’s quality of life.

“We are leveraging and growing our capabilities to deliver value for specific patient populations new to UCB – for example, people with Myasthenia Gravis (MG) and Idiopathic Thrombocytopenic Purpura (ITP). And, while MG and ITP have IgG autoantibody-mediation in common, they are quite distinct conditions each with unique patient experiences. We are striving to understand the unique factors which differentiate individual patient experiences for people with these conditions and tailoring our solutions to solve for these unique needs.

“Currently, we’re proud to be actively engaging with patient and advocacy organizations around the world: Bolstering our knowledge, centering our activities on differentiating individual experiences, and ensuring the views of people who could one day benefit from rozanolixizumab are taken into account as early as possible.

“We believe that our science, combined with our commitment to understanding the real unmet needs of patients, provides us with an opportunity to go far beyond current treatments. By redefining treatment goals and patient experiences, we have a unique and exciting opportunity to make a real difference.”